Industry News (Protease Inhibitors)

Agenerase Data Presented at Glasgow Meeting

Published in AIDS Weekly, November 23rd, 1998

Double protease inhibitor (PI) therapy including amprenavir (Agenerase; Glaxo Wellcome) significantly reduced viral replication and appears to be well-tolerated through 48 weeks in a small, pilot study in HIV patients.

The results were presented at the 4th International Congress on Drug Therapy in HIV Infection, held in Glasgow, Scotland, during November 1998. The study was the first to evaluate the safety and efficacy of Agenerase in a double PI regimen in the absence of nucleoside reverse transcriptase inhibitor (NRTI) therapy.

Results of a second study presented at Glasgow suggested patients previously treated with Agenerase can be treated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-11-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry